文献速递慢性肾脏病急性肾损伤肾移植

跨性别与性别多元人群的肾脏健康及性别肯定激素治疗

Kidney Health and Gender-Affirming Hormone Therapy for Transgender and Gender Diverse Individuals.
PubMed 文献 · Clin J Am Soc Nephrol · 2025-09-05

本综述探讨性别肯定激素治疗(GAHT)对跨性别与性别多元(TGD)人群肾脏健康的影响。GAHT影响肌酐和胱抑素C等eGFR生物标志物,现有性别特异性eGFR公式可能误判肾功能。雌激素可能具有肾脏保护作用而睾酮可能增加风险,但长期数据仍匮乏。

要点

  • GAHT改变肌酐和胱抑素C水平,现有eGFR公式可能误判TGD人群肾功能。
  • 睾酮治疗常升高血清肌酐,雌激素治疗可能降低肌酐或对其无影响。
  • 雌激素可能提供肾脏保护,睾酮可能增加AKI和CKD进展风险。

核心结论

  • GAHT影响eGFR生物标志物及CKD和AKI风险,但长期数据不足,需纵向研究明确TGD人群的eGFR估算和肾脏结局。

研究设计与样本

  • 叙述性综述,聚焦TGD人群GAHT对肾脏健康的影响。

主要发现

  • 睾酮治疗常升高血清肌酐,雌激素治疗可能降低血清肌酐或对其无影响。
  • 雌激素可能提供肾脏保护,睾酮可能增加肾脏风险。
  • 现有性别特异性eGFR公式可能误判TGD个体的肾功能,导致误诊或CKD分期错误。
  • GAHT可能通过多种因素影响CKD进展和AKI发生率。
  • 肾脏移植需考虑激素治疗对移植物和患者存活的影响、药物相互作用及解剖挑战。

临床怎么用

  • 解读TGD人群肾功能时需注意GAHT对肌酐和胱抑素C的影响,避免仅凭性别特异性eGFR公式误判。
  • 关注GAHT使用者的CKD进展和AKI风险,尤其是睾酮治疗者。
  • 肾移植评估中需综合考虑激素治疗、药物相互作用及解剖因素。

局限性

  • 肾脏病登记和国家数据库缺乏TGD人群的包容性数据,限制了对GAHT肾脏影响的理解。
  • 关于GAHT对CKD和AKI发生率及进展的长期影响数据不足。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

This review examines the effects of gender-affirming hormone therapy (GAHT) on kidney health in transgender and gender diverse (TGD) populations, which face significant challenges in accessing medical care. GAHT typically involves estrogen therapy for transgender women and transfeminine individuals, testosterone therapy for transgender men and transmasculine individuals, and therapy regimens for individuals who are nonbinary or identify with another gender not culturally assigned to their sex assigned at birth. Hormone therapy influences biomarkers such as creatinine and cystatin C, which are used in eGFR. Current eGFR equations, reliant on sex-specific factors, may misrepresent kidney function in TGD individuals, leading to misdiagnosis or misclassification of kidney disease stages. GAHT alters serum creatinine (SCr) and cystatin C differently in individuals who use masculinizing or feminizing hormones. Testosterone therapy often raises SCr, while estrogen therapy may lower or has no effect on SCr levels. In addition, GAHT can affect CKD progression and the incidence of AKI due to a myriad of factors including hormonal effects. Estrogen may offer renal protection, while testosterone may elevate risks. Clearly, more data are needed, especially concerning the long-term effects of GAHT on CKD and AKI incidence and progression among TGD individuals. Kidney transplant considerations for TGD patients are complex, involving factors such as the effect of hormone therapy on allograft and patient survivals, drug-drug interactions, and unique anatomical challenges The lack of inclusive data in kidney disease registries and national databases for TGD populations limits the understanding of the effect of GAHT on kidney health. This narrative review calls for comprehensive and longitudinal research to better define eGFR estimation in TGD individuals using GAHT and the broader implications of GAHT on kidney health outcomes.

来源:Clin J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Reema P, Grock S, Wolfe HL, et al. Kidney Health and Gender-Affirming Hormone Therapy for Transgender and Gender Diverse Individuals. Clin J Am Soc Nephrol. 2025. PMID: 40911365. doi:10.2215/CJN.0000000886

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。